Cutaneous Leukocytoclastic Vasculitis as a rare adverse event of infliximab in Crohn's disease: a case report.

Houssam El Mourad, Esraa Alsayed, Tamadar Al Doheyan, Yasser Alomar, Othman Alharbi

Abstract readCase Reports

In one paragraph

Article in Oxford medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Houssam El MouradGastroenterology & Hepatology Department, King Saud University, alyasmmen, street 140, home3-4 Riyadh, Saudi Arabia.ORCID https://orcid.org/0009-0004-5455-6191

Esraa AlsayedGastroenterology & Hepatology Department, King Saud University, alyasmmen, street 140, home3-4 Riyadh, Saudi Arabia.

Tamadar Al DoheyanPathology Department, King Saud University, Riyadh, Saudi Arabia.

Yasser AlomarGastroenterology & Hepatology Department, King Saud University, alyasmmen, street 140, home3-4 Riyadh, Saudi Arabia.

Othman AlharbiGastroenterology & Hepatology Department, King Saud University, alyasmmen, street 140, home3-4 Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leukocytoclastic vasculitis (LCV) is a rare, immune-mediated small-vessel vasculitis that can be triggered by infections, autoimmune diseases, or medications, including biologic therapies. We present a case of a patient with Crohn's disease who developed biopsy proven LCV during longterm infliximab therapy. After four years of sustained remission on infliximab, she developed cutaneous palpable purpura affecting the lower extremities. Laboratory evaluation excluded systemic vasculitis, infection, and other secondary causes. Histopathology confirmed leukocytoclastic vasculitis. Discontinuation of infliximab, led to complete resolution of skin lesions. This case underscores the importance of clinician awareness of rare biologic-associated adverse effects and highlights the need for timely recognition and management to prevent systemic involvement.

Indexed as

adverse eventanti-TNFCrohn’s diseaseinfliximableukocytoclastic vasculitis

Identifiers

PMID42117128

DOI10.1093/omcr/omag067

PMCPMC13157627

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.